| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics
|
Jun 18, 2026 | BUY |
Buy
+105.6% avg upside
15 analysts
|
$12.00
78.40% Upside
|
· |
|
VSTM
Verastem
|
Jun 17, 2026 | BUY |
Strong Buy
+260.2% avg upside
23 analysts
|
$18.00
336.85% Upside
|
· |
|
ENGN
enGene Holdings
|
Jun 16, 2026 | BUY |
Buy
+481.4% avg upside
13 analysts
|
$4.00
132.50% Upside
|
+0.0% |
|
SNDX
Syndax Pharmaceuticals
|
Jun 15, 2026 | BUY |
Strong Buy
+88.8% avg upside
27 analysts
|
$40.00
110.46% Upside
|
-0.9% |
|
CADL
Candel Therapeutics
|
Jun 02, 2026 | BUY |
Strong Buy
+112.6% avg upside
10 analysts
|
$23.00
176.73% Upside
|
+3.6% |
|
MNPR
Monopar Therapeutics Inc
|
Jun 02, 2026 | BUY |
Strong Buy
+45.9% avg upside
18 analysts
|
$105.00
55.71% Upside
|
· |
|
IBRX
ImmunityBio
|
Jun 02, 2026 | BUY |
Strong Buy
+52.6% avg upside
12 analysts
|
$15.00
103.79% Upside
|
· |
|
CRBP
Corbus Pharmaceuticals
|
Jun 02, 2026 | BUY |
Strong Buy
+337.2% avg upside
20 analysts
|
$40.00
384.25% Upside
|
· |
|
IMNM
Immunome
|
Jun 01, 2026 | BUY |
Strong Buy
+83.0% avg upside
16 analysts
|
$40.00
113.44% Upside
|
-10.8% |
|
ZNTL
Zentalis Pharmaceuticals
|
May 26, 2026 | BUY |
Buy
+292.3% avg upside
16 analysts
|
$10.00
170.26% Upside
|
-9.6% |
|
STRO
Sutro Biopharma
|
May 26, 2026 | BUY |
Strong Buy
+31.6% avg upside
20 analysts
|
$50.00
68.70% Upside
|
+5.2% |
|
NBP
NovaBridge Biosciences
|
May 26, 2026 | BUY |
Strong Buy
+1309.7% avg upside
14 analysts
|
$9.00
500.08% Upside
|
· |
|
AURA
Aura Biosciences Inc
|
May 26, 2026 | BUY |
Strong Buy
+233.5% avg upside
9 analysts
|
$24.00
278.49% Upside
|
-15.8% |
|
TARA
Protara Therapeutics
|
May 20, 2026 | BUY |
Strong Buy
+1154.4% avg upside
21 analysts
|
$27.00
578.45% Upside
|
-18.1% |
|
CGON
CG Oncology, Inc.
|
May 18, 2026 | BUY |
Strong Buy
+41.1% avg upside
17 analysts
|
$100.00
63.77% Upside
|
-2.9% |
|
KROS
Keros Therapeutics
|
May 15, 2026 | BUY |
Strong Buy
+139.0% avg upside
21 analysts
|
$20.00
87.81% Upside
|
+0.0% |
|
ERAS
Erasca
|
May 12, 2026 | BUY |
Strong Buy
+39.0% avg upside
14 analysts
|
$20.00
46.33% Upside
|
+34.7% |
|
FHTX
Foghorn Therapeutics
|
May 08, 2026 | BUY |
Strong Buy
+187.5% avg upside
17 analysts
|
$13.00
213.24% Upside
|
-3.6% |
|
SRRK
Scholar Rock Holding
|
May 08, 2026 | BUY |
Strong Buy
+20.1% avg upside
23 analysts
|
$65.00
37.39% Upside
|
-3.0% |
|
TCRX
TScan Therapeutics
|
May 06, 2026 | BUY |
Strong Buy
+823.9% avg upside
12 analysts
|
$7.00
660.90% Upside
|
-28.0% |
|
HOWL
Werewolf Therapeutics
|
Dec 19, 2025 | BUY |
Strong Buy
+1864.2% avg upside
8 analysts
|
$4.00
1038.64% Upside
|
-49.9% |
|
IMA
ImageneBio
|
Nov 11, 2024 | BUY |
Strong Buy
+179.6% avg upside
12 analysts
|
$4.00
33.34% Downside
|
-59.0% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.